Literature DB >> 21801158

Herlitz junctional epidermolysis bullosa: diagnostic features, mutational profile, incidence and population carrier frequency in the Netherlands.

W Y Yuen1, H H Lemmink, K K van Dijk-Bos, R J Sinke, M F Jonkman.   

Abstract

BACKGROUND: Junctional epidermolysis bullosa, type Herlitz (JEB-H) is a lethal, autosomal recessive blistering disease caused by null mutations in the genes coding for the lamina lucida/densa adhesion protein laminin-332 (LAMB3, LAMA3 and LAMC2).
OBJECTIVES: To present the diagnostic features and molecular analyses of all 22 patients with JEB-H in the Dutch Epidermolysis Bullosa Registry between 1988 and 2011, and to calculate the disease incidence and carrier frequency in the Netherlands.
METHODS: All patients were analysed with immunofluorescence antigen mapping (IF), electron microscopy (EM) and molecular analysis.
RESULTS: The mean lifespan of our patients with JEB-H was 5·8 months (range 0·5-32·6). IF showed absent (91%) or strongly reduced (9%) staining for laminin-332 with monoclonal antibody GB3. In EM the hemidesmosomes and sub-basal dense plates were hypoplastic or absent. We identified mutations in all 22 patients: in 19 we found LAMB3 mutations, in two LAMA3 mutations, and in one LAMC2 mutations. We found three novel splice site mutations in LAMB3: (i) c.29-2A>G resulting in an out-of-frame skip of exon 3 and a premature termination codon (PTC); (ii) c.1289-2_1296del10 leading to an out-of-frame skip of exon 12 and a PTC; and (iii) c.3228+1G>T leading to an exon 21 skip.
CONCLUSIONS: All diagnostic tools should be evaluated to clarify the diagnosis of JEB-H. We have identified 11 different mutations in 22 patients with JEB-H, three of them novel. In the Netherlands the incidence rate of JEB-H is 4·0 per one million live births. The carrier frequency of a JEB-H mutation in the Dutch population is 1 in 249.
© 2011 The Authors. BJD © 2011 British Association of Dermatologists 2011.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21801158     DOI: 10.1111/j.1365-2133.2011.10553.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  10 in total

Review 1.  Laminin 332 in junctional epidermolysis bullosa.

Authors:  Dimitra Kiritsi; Cristina Has; Leena Bruckner-Tuderman
Journal:  Cell Adh Migr       Date:  2012-10-17       Impact factor: 3.405

2.  Immunogenicity of decidual stromal cells in an epidermolysis bullosa patient and in allogeneic hematopoietic stem cell transplantation patients.

Authors:  Helen Kaipe; Lena-Maria Carlson; Tom Erkers; Silvia Nava; Pia Molldén; Britt Gustafsson; Hua Qian; Xiaoguang Li; Takashi Hashimoto; Behnam Sadeghi; Mats Alheim; Olle Ringdén
Journal:  Stem Cells Dev       Date:  2015-03-13       Impact factor: 3.272

3.  Eye Involvement and Management in Inherited Epidermolysis Bullosa.

Authors:  Yasmine Bachir; Alejandra Daruich; Couanon Marie; Matthieu P Robert; Dominique Bremond-Gignac
Journal:  Drugs       Date:  2022-09-08       Impact factor: 11.431

4.  Nutritional outcomes in children with epidermolysis bullosa: the experiences of two centers in Korea.

Authors:  Kyu-Yeun Kim; Ran Namgung; Soon Min Lee; Soo Chan Kim; Ho Sun Eun; Min Soo Park; Kook In Park; Chul Lee
Journal:  Yonsei Med J       Date:  2014-01       Impact factor: 2.759

5.  Identification of a Novel Mutation of LAMB3 Gene in a Lybian Patient with Hereditary Epidermolysis Bullosa by Whole Exome Sequencing.

Authors:  Nadia Laroussi; Olfa Messaoud; Mariem Chargui; Chaima Ben Fayala; Abdelaziz Elahlafi; Mourad Mokni; Anu Bashamboo; Kenneth McElreavey; Mohamed Samir Boubaker; Houda Yacoub Youssef; Sonia Abdelhak
Journal:  Ann Dermatol       Date:  2017-03-24       Impact factor: 1.444

Review 6.  Epidermolysis Bullosa-Associated Squamous Cell Carcinoma: From Pathogenesis to Therapeutic Perspectives.

Authors:  Angelo Giuseppe Condorelli; Elena Dellambra; Elena Logli; Giovanna Zambruno; Daniele Castiglia
Journal:  Int J Mol Sci       Date:  2019-11-14       Impact factor: 5.923

7.  Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa.

Authors:  C Has; L Liu; M C Bolling; A V Charlesworth; M El Hachem; M J Escámez; I Fuentes; S Büchel; R Hiremagalore; G Pohla-Gubo; P C van den Akker; K Wertheim-Tysarowska; G Zambruno
Journal:  Br J Dermatol       Date:  2019-08-09       Impact factor: 9.302

8.  Keratinocyte footprint assay discriminates antilaminin-332 pemphigoid from all other forms of pemphigoid diseases.

Authors:  F Giurdanella; A M Nijenhuis; G F H Diercks; M F Jonkman; H H Pas
Journal:  Br J Dermatol       Date:  2019-08-09       Impact factor: 9.302

9.  Identification of a novel homozygous LAMB3 mutation in a Chinese male with junctional epidermolysis bullosa and severe urethra stenosis: A case report.

Authors:  Wei Wang; Qiang Guo; Jinshan Chen; Xi Zhang; Chengyong Li; Shuangping Li; Jialin Liang; Chuan Hao; Jingqi Wang
Journal:  Front Genet       Date:  2022-09-30       Impact factor: 4.772

10.  Epidermolysis Bullosa in Chinese Patients: Genetic Analysis and Mutation Landscape in 57 Pedigrees and Sporadic Cases.

Authors:  Yueqian Yu; Zhenzhen Wang; Zihao Mi; Lele Sun; Xi'an Fu; Gongqi Yu; Zheng Pang; Hong Liu; Furen Zhang
Journal:  Acta Derm Venereol       Date:  2021-07-15       Impact factor: 3.875

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.